|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-3-14
|
|
pubmed:abstractText |
Abrogation of negative feedback control represents a fundamental requirement for aberrantly activated signaling pathways to promote malignant transformation and resistance to therapy. Here we identify URI, which encodes a mitochondrial inhibitor of PP1? and PP1?-mediated feedback inhibition of S6K1-BAD survival signaling, as an oncogene amplified and overexpressed in ovarian cancer cell lines and human ovarian carcinomas. URI is an "addicting" oncogene selectively required for the survival of ovarian cancer cells with increased URI copy number. By constitutively detaining PP1? in inactive complexes, URI sustains S6K1 survival signaling under growth factor-limiting conditions and mediates resistance of cells to cisplatin. Thus, oncogenic activation of URI defines an important mechanism for activating mitochondrial S6K1-BAD signaling and promoting cell survival through disabling PP1?-dependent negative feedback inhibition.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1878-3686
|
|
pubmed:author |
pubmed-author:CaduffRosmarieR,
pubmed-author:DjouderNabilN,
pubmed-author:Heinzelmann-SchwarzViolaV,
pubmed-author:HelblingMarianneM,
pubmed-author:HenziNicoN,
pubmed-author:JacobFrancisF,
pubmed-author:KrekWilhelmW,
pubmed-author:MetzlerStefan ChristianSC,
pubmed-author:MochHolgerH,
pubmed-author:SoltermannAlexA,
pubmed-author:TheurillatJean-PhilippeJP,
pubmed-author:ZimmermannAnna-KathrinAK
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
8
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
317-32
|
|
pubmed:meshHeading |
pubmed-meshheading:21397856-Animals,
pubmed-meshheading:21397856-Cell Line, Tumor,
pubmed-meshheading:21397856-Cell Survival,
pubmed-meshheading:21397856-Female,
pubmed-meshheading:21397856-Gene Amplification,
pubmed-meshheading:21397856-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21397856-HeLa Cells,
pubmed-meshheading:21397856-Humans,
pubmed-meshheading:21397856-Immunoblotting,
pubmed-meshheading:21397856-Immunohistochemistry,
pubmed-meshheading:21397856-In Situ Hybridization, Fluorescence,
pubmed-meshheading:21397856-Intracellular Signaling Peptides and Proteins,
pubmed-meshheading:21397856-Kaplan-Meier Estimate,
pubmed-meshheading:21397856-Mice,
pubmed-meshheading:21397856-Mice, Nude,
pubmed-meshheading:21397856-Neoplasms, Experimental,
pubmed-meshheading:21397856-Oncogene Proteins,
pubmed-meshheading:21397856-Ovarian Neoplasms,
pubmed-meshheading:21397856-Protein Binding,
pubmed-meshheading:21397856-Protein Phosphatase 1,
pubmed-meshheading:21397856-RNA Interference,
pubmed-meshheading:21397856-Ribosomal Protein S6 Kinases,
pubmed-meshheading:21397856-Transplantation, Heterologous,
pubmed-meshheading:21397856-Tumor Burden,
pubmed-meshheading:21397856-bcl-Associated Death Protein
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
URI is an oncogene amplified in ovarian cancer cells and is required for their survival.
|
|
pubmed:affiliation |
Institute of Cell Biology, ETH Zurich, 8093 Zurich, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
